PHARMARON (03759) · Company profile · Eqvero

PHARMARON

03759HKEX

Unit: CNY	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	14.07 bn CNY	12.27 bn CNY	11.53 bn CNY	10.24 bn CNY	7.42 bn CNY
Cost of revenue	8.02 bn CNY	7.04 bn CNY	6.51 bn CNY	5.81 bn CNY	4.27 bn CNY
Research and development expense	576.02 m CNY	469.26 m CNY	448.28 m CNY	282.33 m CNY	151.78 m CNY
Selling, general and administrative expense	2.04 bn CNY	1.84 bn CNY	1.86 bn CNY	1.73 bn CNY	1.02 bn CNY
Operating profit after depreciation	2.05 bn CNY	1.72 bn CNY	1.69 bn CNY	1.67 bn CNY	1.45 bn CNY
Operating profit before depreciation	3.23 bn CNY	2.77 bn CNY	2.61 bn CNY	2.36 bn CNY	1.95 bn CNY
EBIT	2.05 bn CNY	1.72 bn CNY	1.69 bn CNY	1.67 bn CNY	1.45 bn CNY
EBITDA	3.23 bn CNY	2.77 bn CNY	2.61 bn CNY	2.36 bn CNY	1.95 bn CNY
Interest expense	218.1 m CNY	261.34 m CNY	213.5 m CNY	191.7 m CNY	117.74 m CNY
Profit before tax	1.91 bn CNY	2.09 bn CNY	1.84 bn CNY	1.67 bn CNY	1.91 bn CNY
Income tax expense	357.52 m CNY	377.1 m CNY	256.11 m CNY	314.25 m CNY	290.92 m CNY
Income before extraordinary items	1.66 bn CNY	1.79 bn CNY	1.6 bn CNY	1.37 bn CNY	1.66 bn CNY
Common dividends	366 m CNY	354.19 m CNY	357.48 m CNY	1.19 bn CNY	357.38 m CNY
Total dividends	366 m CNY	354.19 m CNY	357.48 m CNY	1.19 bn CNY	357.38 m CNY

Quotes are end-of-day data. Content is for research purposes and is not investment advice.